Understanding the 'Durable Effect' Concept of B-cell Modulating Therapies

RecruitingOBSERVATIONAL

Enrollment

100

Participants

Timeline

Start Date

October 27, 2021

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions

Relapsing-remitting Multiple Sclerosis

Interventions

DRUG

Anti-CD20 antibody

Study participants receive an anti-CD20 antibody according to the summary of product characteristics.

Trial Locations (1)

RECRUITING

Heinrich-Heine University, Duesseldorf, Düsseldorf